The Drug-Drug Interaction between Erlotinib and OSI-930 Is Mediated through Aldehyde Oxidase Inhibition
Drug Metabolism and Disposition · 2024
DOI: 10.1124/dmd.124.001802 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2024. Verfasst von Lloyd Wei Tat Tang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Groton, Connecticut lloydweitat.tang@pfizer.com. Hauptthemen laut MEDLINE: Aldehyde Oxidase, Erlotinib Hydrochloride, Drug Interactions. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Groton, Connecticut lloydweitat.tang@pfizer.com.
- Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Groton, Connecticut.
ORCID-Profile: Lloyd Wei Tat Tang
Zitieren
APA
Tang, L. W. T., Shi, Y., Sharma, R., & Obach, R. S. (2024). The Drug-Drug Interaction between Erlotinib and OSI-930 Is Mediated through Aldehyde Oxidase Inhibition. Drug Metabolism and Disposition. https://doi.org/10.1124/dmd.124.001802
Vancouver
Tang LWT, Shi Y, Sharma R, Obach RS. The Drug-Drug Interaction between Erlotinib and OSI-930 Is Mediated through Aldehyde Oxidase Inhibition. Drug Metabolism and Disposition. 2024. doi:10.1124/dmd.124.001802
BibTeX
@article{Tang2024,
author = {Tang, Lloyd Wei Tat and Shi, Yuanyuan and Sharma, Raman and Obach, R Scott},
title = {The Drug-Drug Interaction between Erlotinib and OSI-930 Is Mediated through Aldehyde Oxidase Inhibition},
journal = {Drug Metabolism and Disposition},
year = {2024},
doi = {10.1124/dmd.124.001802}
}
EUVIMED